Rnai Drug Delivery Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, China, Germany, Canada - Size and Forecast 2024-2028

RNAi Drug Delivery Market Size 2024-2028

The RNAi drug delivery market size is estimated to grow by USD 193.2 billion at a CAGR of 27.16% between 2023 and 2028. The high target affinity and specificity of RNAi therapeutics make them attractive for treating a wide range of diseases, including neurological disorders. Increasing research activities in the pharmaceutical and biotechnology sectors are leading to the development of new RNAi therapeutics and expanding their applications. The increasing prevalence of neurological disorders, such as Alzheimer's and Parkinson's disease, is driving the demand for effective treatments, further fueling market growth in this area. It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2018 to 2022.

What will be the size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Segmentation

By Technology

The market share growth by the nanoparticle drug delivery segment will be significant during the forecast period. Nanoparticle drug delivery systems are modern technologies that are rapidly developing technology materials in the nanoscale range and are employed to serve as therapeutic agents to targeted sites in a controlled manner. Nanotechnology provides numerous advantages in the treatment of chronic human diseases by delivering precise medications to specified locations and targets.

Get a glance at the market contribution of various segments View the PDF Sample

The nanoparticle drug delivery segment showed a gradual increase in the market share of USD 14.40 billion in 2018. Characteristics of nanoparticles, such as distinctive size, are useful for the efficient delivery of RNAi therapeutics. As a result, nanoparticle drug delivery systems are used in the treatment of cancer, and it is an emerging therapeutic strategy for combating cancer. Thus, the application of nanoparticle drug delivery systems in cancer treatment coupled with the increasing cases of cancer will drive the growth of the segment and, in turn, the market in focus during the forecast period

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In North America, there is a rise in the number of cancer and metabolic diseases due to excessive smoking and consumption of alcohol. The availability of improved diagnostic modalities has made it possible to identify several rare diseases, as a result of which many market vendors, along with researchers, are discovering and coming up with RNAi therapies. Currently, RNAi drug delivery is experiencing high demand in the US. The region benefits from advanced research and manufacturing facilities, contributing significantly to the rapid growth of the market in North America.

For instance, in April 2020, Alnylam partnered with Dicerna, a subsidiary of Novo Nordisk, to collaborate on developing RNAi therapeutics for treating alpha-1 liver disease. This collaboration highlights the region's leadership in RNAi drug development and underscores the importance of advanced technologies and research capabilities in driving market expansion. The integration of Deoxynucleotide Triphosphates (dNTPs) is crucial in RNAi drug delivery systems, supporting the synthesis of RNA molecules essential for therapeutic applications. As the demand for RNAi-based therapies grows, fueled by such collaborations and technological advancements, the market for dNTPs is expected to witness robust growth throughout the forecast period.

Market Dynamics and Customer Landscape

Key Market Driver

The high target affinity and specificity of RNAi therapeutics are the key drivers for the growth of the market.  RNAi therapeutics demonstrate remarkable effectiveness against their specific targets. RNAi molecules bind to target genes with exceptional affinity, facilitated by complementary base pairing that involves hydrogen bond formation in nucleic acids. This high-affinity binding enables RNAi and antisense oligonucleotides to regulate gene expression through various mechanisms.

Further, some key advantages of RNAi therapeutics include their ability to target virtually any gene in the genome, their high potency and long-lasting effects, and their ability to be administered through multiple routes, including intravenous, subcutaneous, and inhalation delivery. These benefits are complemented by advancements in these technologies such as Aptamer Drug Delivery Technology, Nanoparticle Drug Delivery Technology, and Nanoparticle-based delivery systems. In fields like Oncology, Ophthalmology, and for treating Ocular Disorders, these RNAi therapeutics hold promise for personalized medicine approaches. These factors are expected to lead to the introduction and approval of new RNAi drugs, driving market growth during the forecast period.

Significant Market Trends

The increasing R&D for RNAi therapy by vendors is the primary trend in the market. Vendors operating in the market have increased their focus on R&D for RNAi therapy to expand their offerings. For instance, In June 2022, Alnylam initiated platform advancements that enabled the development of a new conjugate technology, C16. With a new conjugate, RNAi therapy can target new extrahepatic tissues, including the eye, the lung, and the central nervous system. Phase 1 ALN-APP program in early-onset Alzheimer's disease is the first clinical program to utilize C16.

Moreover, in November 2021, Novo Nordisk entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). Dicerna focuses on RNAi-based therapeutics. Moreover, the RNAi platform from Dicerna to Novo Nordisk's already existing research technology platforms strengthens the company's objective of utilizing a wide variety of technology platforms that apply to all its therapeutic emphasis areas. Such trends will positively impact the growth of the market in focus during the forecast period.

Major Market Challenge

The high price of RNAi drugs is the major challenge in the market. RNAi-based drugs are very effective for the treatment of various chronic diseases, However, their high price makes them unaffordable for the patients. Manufacturers of RNAi-based drugs are investing huge sums in the R&D of these kinds of therapies. Factors such as a highly technically skilled workforce and complex manufacturing and scaling-up facilities are responsible for the high prices of these drugs.

Moreover, after 16 years of continuous research and USD 2.5 billion in investments, Alnylam offers ONPATTRO for the treatment of hATTR amyloidosis, which costs around USD 450,000 per patient. However, most countries across the world do not have reimbursement policies for such expensive therapies. Thus, the high cost of RNAi drugs will negatively impact the growth of the market in focus during the forecast period.

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major RNAi Drug Delivery Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product launches, to enhance their presence in the market.

Arbutus Biopharma Corp.:  The company offers RNAi drug delivery solutions such as AB 729 is an RNA interference therapeutic targeted to hepatocytes using Arbutus novel covalently conjugated N acetylgalactosamine delivery technology that enables subcutaneous delivery.

The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including:

• Alnylam Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Bayer AG
• Benitec Biopharma Inc.
• BioNTech SE
• Bristol Myers Squibb Co.
• CureVac AG
• e therapeutics plc
• F. Hoffmann La Roche Ltd.
• Novartis AG
• Novo Nordisk AS
• Phio Pharmaceuticals
• Sanofi
• Silence Therapeutics plc
• Silenseed Inc.
• siRNAgen Therapeutics Corp.
• Sirnaomics Inc.
• Sylentis S.A.
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Segment Overview

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Technology Outlook
  • Nanoparticle drug delivery
  • Pulmonary drug delivery
  • Nucleic acid drug delivery
  • Aptamer drug delivery

• Application Outlook 
  • Infectious diseases
  • Oncology
  • Cardiology
  • Neurology
  • Others

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World
    • Australia
    • Brazil
    • Saudi Arabia

You may also interested in below market reports:

• Oligonucleotide Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, Japan - Size and Forecast
• Transfection Technologies Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, China, UK, Germany, France - Size and Forecast
• Oligonucleotide Synthesis Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, China, Japan - Size and Forecast

Market Analyst Overview:

The market is revolutionizing healthcare by targeting a spectrum of conditions, from chronic metabolic disorders and cardiovascular diseases (CVDs) to urological, oncological, and genetic disorders. Utilizing small interfering RNA (siRNA), microRNAs (miRNA), and antisense oligonucleotide (ASO) therapeutics, RNAi therapies aim to silence genes and modulate disease pathways at a molecular level. Advances in synthetic delivery carriers, bio vectors, and nanocarriers enable precise and efficient delivery of RNA molecules to altered cellular molecules and specific tissues. This approach is pivotal in personalized medicines and enhancing molecular diagnostics capabilities, potentially transforming treatment outcomes for patients with rare genetic diseases. With ongoing research in RNA synthesis and development of pipeline products including drugs and vaccines, RNAi therapeutics hold promise in combatting emerging health challenges such as coronavirus disease and other viral infections. The market's growth is bolstered by expanding healthcare infrastructure and increasing investment in innovative RNA-based treatments across hospitals, clinics, and research institutions worldwide.

Further, the market is advancing treatments for a wide range of conditions, including cardiovascular disorders, urological disorders, and oncological disorders, particularly relevant to the geriatric population. Utilizing RNA interference (RNAi) therapeutics and mRNA therapeutics, researchers are targeting specific disease pathways with precision, aiming to mitigate symptoms and improve outcomes. These therapies are also pivotal in HIV vaccine trials and developing antiviral drugs by targeting viral antigens and altering cellular metabolites. Challenges such as RNases and immunogenicity are addressed through innovative delivery systems that protect RNA molecules until they reach the cytoplasmic membrane of targeted cells. The expansion of RNAi technologies is enhancing therapeutic possibilities in hospitals and clinics, offering new avenues for personalized medicine and potentially transforming how complex diseases are treated in clinical settings. As research progresses, RNAi drug delivery holds promise for addressing unmet medical needs across diverse patient populations.

View PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch